S
Shariq Haider
Researcher at McMaster University
Publications - 50
Citations - 1737
Shariq Haider is an academic researcher from McMaster University. The author has contributed to research in topics: Posaconazole & Population. The author has an hindex of 15, co-authored 47 publications receiving 1306 citations. Previous affiliations of Shariq Haider include Juravinski Hospital & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M. Marty,Per Ljungman,Roy F. Chemaly,Johan Maertens,Sanjeet Dadwal,Rafael F. Duarte,Shariq Haider,Andrew J. Ullmann,Yuta Katayama,Janice M. Brown,Kathleen M. Mullane,Michael Boeckh,Emily A. Blumberg,Hermann Einsele,David R. Snydman,Yoshinobu Kanda,Mark J. DiNubile,Valerie L Teal,Hong Wan,Yoshihiko Murata,Nicholas A. Kartsonis,Randi Y. Leavitt,Cyrus Badshah +22 more
TL;DR: Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo, and the frequency and severity of adverse events were similar in the two groups overall.
Journal ArticleDOI
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
Oliver A. Cornely,Rafael F. Duarte,Shariq Haider,Pranatharthi H. Chandrasekar,David Helfgott,Javier Lopez Jimenez,Anna Candoni,Issam I Raad,Michel Laverdière,Amelia Langston,Nicholas A. Kartsonis,Marlou L. P. S. van Iersel,Nancy A. Connelly,Hetty Waskin +13 more
TL;DR: In patients at high risk for invasive fungal disease, 300 mg posaconazole (as tablets) once daily was well tolerated and demonstrated a safety profile similar to that reported for posaconzole oral suspension.
Journal ArticleDOI
Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia
Rafael F. Duarte,Javier López-Jiménez,Oliver A. Cornely,Michel Laverdière,David Helfgott,Shariq Haider,Pranatharthi H. Chandrasekar,Amelia Langston,John R. Perfect,Lei Ma,Marlou L. P. S. van Iersel,Nancy A. Connelly,Nicholas A. Kartsonis,Hetty Waskin +13 more
TL;DR: Posaconazole tablets were generally well tolerated in high-risk neutropenic patients and identified the dose of posaconazoles that would provide exposure within a predefined range of exposures.
Journal ArticleDOI
Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study
Marina B. Klein,Sahar Saeed,Hong Yang,Jeffrey I. Cohen,Brian Conway,Curtis Cooper,Pierre Côté,Joseph Cox,John Gill,David Haase,Shariq Haider,Julio S. G. Montaner,Neora Pick,Anita Rachlis,Danielle Rouleau,Roger Sandre,Mark W. Tyndall,Sharon Walmsley +17 more
TL;DR: The growing burden of chronic HCV infection is expected to result in dramatic increases in the rates of cirrhosis, liver failure, hepatocellular carcinoma, transplant needs and related annual healthcare costs in Canada and worldwide.
Journal ArticleDOI
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Sergio Borgia,Janet Dearden,Eric M. Yoshida,Stephen D. Shafran,Ashley Brown,Ziv Ben-Ari,Matthew E. Cramp,Curtis Cooper,Matthew Foxton,Conrado M Fernández Rodríguez,Rafael Esteban,Robert H. Hyland,Sophia Lu,Brian J. Kirby,Amy Meng,Svetlana Markova,Hadas Dvory-Sobol,Anu Osinusi,Rafael Bruck,Javier Ampuero,Stephen D. Ryder,Kosh Agarwal,Raymond Fox,David R. Shaw,Shariq Haider,Bernard Willems,Yoav Lurie,Jose Luis Calleja,Edward Gane +28 more
TL;DR: Treatment with sofosbuvir/velpatasvir for 12 weeks was safe and effective in patients with HCV infection and ESRD who were undergoing dialysis, resulting in a cure rate of 95% in patients in this phase 2, single-arm study.